Go to the list of all blogs
Anna G's Avatar
published in Blogs
Feb 28, 2022

Lowe's (LOW, $217.75) beats Q4 expectations

Lowe's Companies posted fourth quarter earnings that surpassed expectations. The home improvement company also raised its 2022 outlook, on gaining market shares from its larger rival.

Lowe's adjusted earnings for the three months ending on January 28 came in at $1.78 per share, +33.8% higher from the year-ago quarter well ahead of the Street expectations of $1.71 per share.

Revenues increased +4.9% year-over-year to $21.3 billion, exceeding analysts' estimates of a $20.31 billion. U.S. same-store sales climbed +5%, vs. Refinitiv forecast of a -3.1% decline.

Looking ahead, Lowe's projects 2022 financial year earnings in the range of $13.10 to $13.60 per share, up from its mid-December forecast of $12.25 to $13 per share.

The company expects revenues in the range of $97 billion and $99 billion, a $2 billion improvement from the higher end of its prior forecast. It predicts same-store sales either falling or rising by 1% from 2021 levels.

Interact to see
Advertisement
The Bitwise Solana Staking ETF (BSOL) advanced roughly 18% over the trailing 30 days, closely tracking a sharp rally in Solana (SOL). The move extends a broader recovery, with BSOL up approximately 77% over the past three months from its mid-2026 trough.
MSTY is an actively managed single-stock option income ETF (exchange-traded fund) that writes call options on Strategy (MSTR), formerly MicroStrategy, to generate current income. The portfolio is anchored by U.S. Treasury bills and MSTR option contracts rather than a diversified basket of equities, concentrating exposure in one volatile underlying.
AMDL has surged roughly +64% over the past 30 days, from about $47.59 to $78.10, mirroring a powerful rally in its sole underlying stock, AMD . The fund is a leveraged single-stock ETF (exchange-traded fund) designed to deliver 2x the daily return of AMD, amplifying both gains and losses.
Shares of WAY are declining approximately 14.00% on Thursday, April 30, 2026, falling from a prior close of $25.27 to approximately $21.73 — approaching the stock's 52-week low of $21.09 set on April 10 — as Q1 2026 results released April 29 delivered a headline revenue beat that was immediately overshadowed by Q2 2026 sequential revenue guidance of flat to -1% growth, signaling that the momentum trajectory in healthcare payment software is decelerating materially.
Shares of MAX are declining approximately 15.00% on Thursday, April 30, 2026, falling from a prior close of approximately $10.00 to approximately $8.50, as Q1 2026 results released after Wednesday's close delivered record revenue of $310.0 million — a 17% year-over-year increase that beat the $298.91 million consensus